January4th,2021By Mel J. YeatesAgreeing on antibioticsHoth Therapeutics collaborates with USAMRDC to treat multi-drug resistant bacterial lung infections
December22nd,2020By Mel J. YeatesAmgen licenses AMG 634 to MDGHAMG 634, an investigational treatment for tuberculosis and leprosy, has been licensed to Medicines Development for Global Health
Infectious Disease & VaccinesDecember15th,2020By DDN StaffCOVID-19 vaccine candidate COVI-VAC heads to Phase 1COVI-VAC is a single dose, intranasal live attenuated vaccine for COVID-19
November16th,2020By Mel J. YeatesOX40L and CD30L blockade could improve asthmaStudy suggests that future asthma therapies should target OX40L and CD30L
July7th,2020By DDN StaffAn oral option for gastrointestinal problemsZeposia could help solve the unmet need of more oral drugs for moderate to severe CD and UC patients
July7th,2020By DDN StaffTrying to take pediatric brain tumors down a pegZiopharm Oncology doses first DIPG patient in Phase 1/2 trial of Controlled IL-12
July6th,2020By DDN StaffLooking at the frontrunnersThree compounds are in the spotlight now as new and repurposed drug options are examined for COVID-19
July1st,2020By DDN StaffAnti-inflammatory TAT CARMIL1 discovery offers hope for COVID-19Peptide combination could be effective in reducing damage caused by COVID-19 infections
June29th,2020By DDN StaffGalectin Therapeutics begins enrollment in NASH-RX trialBelapectin has shown ability to prevent the development of esophageal varices in NASH patients
June25th,2020By Mel J. YeatesFDA approves Zogenix’s Fintepla for Dravet syndromeThe FDA has approved Fintepla for Dravet syndrome in patients 2 and older